Close

Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11

April 29, 2016 8:02 AM EDT Send to a Friend
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albuterol ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login